CLAIMS:

1. The use of a compound of the formula I:



(I)

wherein:

ring C is a 5-6-membered heterocyclic moiety which may be saturated or unsaturated, which may be aromatic or non-aromatic, and which contains 1-3 heteroatoms selected independently from O, N and S;

Z is -O-, -NH-, -S- or $-CH_2-$;

R^1 represents hydrogen, C_{1-4}alkyl, C_{1-4}alkoxymethyl, di(C_{1-4}alkoxy)methyl, C_{1-4}alkanoyl, trifluoromethyl, cyano, amino, C_{2-5}alkenyl, C_{2-5}alkynyl, a phenyl group, a benzyl group or a 5-6-membered heterocyclic group with 1-3 heteroatoms, selected independently from O, S and N, which heterocyclic group may be aromatic or non-aromatic and may be saturated (linked via a ring carbon or nitrogen atom) or unsaturated (linked via a ring carbon atom), and which phenyl, benzyl or heterocyclic group may bear on one or more ring carbon atoms up to 5 substituents selected from hydroxy, halogeno, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C_{2-4}alkanoyl, C_{1-4}alkanoylamino, C_{1-4}alkoxycarbonyl, C_{1-4}alkylsulphanyl, C_{1-4}alkylsulphinyl, C_{1-4}alkylsulphonyl, carbamoyl, N-C_{1-4}alkylcarbamoyl, N,N-di(C_{1-4}alkyl)carbamoyl, aminosulphonyl, N-C_{1-4}alkylaminosulphonyl, N,N-di(C_{1-4}alkyl)aminosulphonyl, C_{1-4}alkylsulphonylamino, C_{1-4}alkylamino, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, C_{1-4}haloalkyl, C_{1-4}hydroxyalkoxy, carboxy and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2

substituents selected from oxo, hydroxy, halogeno, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkanoyloxy, trifluoromethyl, cyano, amino, nitro and C_{1-4}alkoxycarbonyl; and additionally R^1 may represent carboxy, C_{3-7}cycloalkyl, C_{3-7}cycloalkylC_{1-3}alkyl, or phenylC_{2-4}alkyl wherein the phenyl moiety may bear up to 5 substituents selected from the list herein defined for a phenyl ring which is directly linked to ring C:

n is an integer from 0 to 5;

m is an integer from 0 to 3;

R^2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkylsulphanyl, $-NR^3R^4$ (wherein R^3 and R^4, which may be the same or different, each represents hydrogen or C_{1-3}alkyl), or R^5X^1- (wherein X^1 represents a direct bond, -O-, $-CH_2$-, -OCO-, carbonyl, -S-, -SO-, $-SO_2$-, $-NR^6CO$-, $-CONR^7$-, $-SO_2NR^8$-, $-NR^9SO_2$- or $-NR^{10}$- (wherein R^6, R^7, R^8, R^9 and R^{10} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl), and R^5 is selected from one of the following eighteen groups:

1) hydrogen or C_{1-5}alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino;

2) C_{1-5}alkylX^2COR^{11} (wherein X^2 represents -O- or $-NR^{12}$- (in which R^{12} represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{11} represents C_{1-3}alkyl, $-NR^{13}R^{14}$ or $-OR^{15}$ (wherein R^{13}, R^{14} and R^{15} which may be the same or different each represents hydrogen, C_{1-3}alkyl, C_{4-5}alkyl or C_{1-3}alkoxyC_{2-3}alkyl));

3) C_{1-5}alkylX^3R^{16} (wherein X^3 represents -O-, -S-, -SO-, $-SO_2$-, -OCO-, $-NR^{17}CO$-, $-CONR^{18}$-, $-SO_2NR^{19}$-, $-NR^{20}SO_2$- or $-NR^{21}$- (wherein R^{17}, R^{18}, R^{19}, R^{20} and R^{21} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{16} represents hydrogen, C_{1-3}alkyl, cyclopentyl, cyclohexyl or a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4}alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}cyanoalkyl and C_{1-4}alkoxycarbonyl);

4) C_{1-5}alkylX^4C_{1-5}alkylX^5R^{22} (wherein X^4 and X^5 which may be the same or different are each -O-, -S-, -SO-, $-SO_2$-, $-NR^{23}CO$-, $-CONR^{24}$-, $-SO_2NR^{25}$-, $-NR^{26}SO_2$- or $-NR^{27}$- (wherein R^{23}, R^{24}, R^{25}, R^{26} and R^{27} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{22} represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl);

5) R^{28} (wherein R^{28} is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl and C_{1-4}alkoxycarbonyl);

6) C_{1-5}alkylR^{28} (wherein R^{28} is as defined herein);

7) C_{2-5}alkenylR^{28} (wherein R^{28} is as defined herein);

8) C_{2-5}alkynylR^{28} (wherein R^{28} is as defined herein);

9) R^{29} (wherein R^{29} represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents on an available carbon atom selected from hydroxy, halogeno, amino, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, C_{1-4}hydroxyalkoxy, carboxy, trifluoromethyl, cyano, $-CONR^{30}R^{31}$ and $-NR^{32}COR^{33}$ (wherein R^{30}, R^{31}, R^{32} and R^{33}, which may be the same or different, each represents hydrogen, C_{1-4}alkyl or C_{1-3}alkoxyC_{2-3}alkyl));

10) C_{1-5}alkylR^{29} (wherein R^{29} is as defined herein);

11) C_{2-5}alkenylR^{29} (wherein R^{29} is as defined herein);

12) C_{2-5}alkynylR^{29} (wherein R^{29} is as defined herein);

13) C_{1-5}alkylX^6R^{29} (wherein X^6 represents -O-, -S-, -SO-, $-SO_2$-, $-NR^{34}CO$-, $-CONR^{35}$-, $-SO_2NR^{36}$-, $-NR^{37}SO_2$- or $-NR^{38}$- (wherein R^{34}, R^{35}, R^{36}, R^{37} and R^{38} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{29} is as defined herein);

14) C_{2-5}alkenylX^7R^{29} (wherein X^7 represents -O-, -S-, -SO-, $-SO_2$-, $-NR^{39}CO$-, $-CONR^{40}$-, $-SO_2NR^{41}$-, $-NR^{42}SO_2$- or $-NR^{43}$- (wherein R^{39}, R^{40}, R^{41}, R^{42} and R^{43} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{29} is as defined herein);

15) C_{2-5}alkynylX^8R^{29} (wherein X^8 represents -O-, -S-, -SO-, $-SO_2$-, $-NR^{44}CO$-, $-CONR^{45}$-, $-SO_2NR^{46}$-, $-NR^{47}SO_2$- or $-NR^{48}$- (wherein R^{44}, R^{45}, R^{46}, R^{47} and R^{48} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{29} is as defined herein);

16) C_{1-3}alkylX^9C_{1-3}alkylR^{29} (wherein X^9 represents -O-, -S-, -SO-, $-SO_2$-, $-NR^{49}CO$-, $-CONR^{50}$-, $-SO_2NR^{51}$-, $-NR^{52}SO_2$- or $-NR^{53}$- (wherein R^{49}, R^{50}, R^{51}, R^{52} and R^{53} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{29} is as defined herein);

17) C_{1-3}alkylX^9C_{1-3}alkylR^{28} (wherein X^9 and R^{28} are as defined herein); and

18) C_{1-3}alkyl$R^{54}C_{1-3}$alkylX^9R^{55} (wherein X^9 is as defined herein and R^{54} and R^{55} are each independently selected from hydrogen, C_{1-3}alkyl, cyclopentyl, cyclohexyl and a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4}alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}cyanoalkyl and C_{1-4}alkoxycarbonyl), with the proviso that R^{54} cannot be hydrogen;

and additionally wherein any C_{1-5}alkyl, C_{2-5}alkenyl or C_{2-5}alkynyl group in R^5X^1- may bear one or more substituents selected from hydroxy, halogeno and amino;

or a salt thereof in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals such as humans.

2. The use of a compound of the formula Ia:



(Ia)

wherein:

ring C, R^1, R^2, n and Z are as defined in claim 1 with the proviso that R^2 is not hydrogen; and

R^{2a} represents hydrogen, halogeno, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkylthio, $-NR^{3a}R^{4a}$ (wherein R^{3a} and R^{4a}, which may be the same or different, each represents hydrogen or C_{1-3}alkyl), or $R^{5a}(CH_2)_{za}X^{1a}$ (wherein R^{5a} is a 5- or 6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-4}alkyl, C_{1-4}hydroxyalkyl and C_{1-4}alkoxy, za is an integer from 0 to 4 and X^{1a} represents a direct bond, -O-, $-CH_2$-, -S-, -SO-, $-SO_2$-, $-NR^{6a}CO$-, $-CONR^{7a}$-, $-SO_2NR^{8a}$-, $-NR^{9a}SO_2$- or $-NR^{10a}$- (wherein R^{6a}, R^{7a}, R^{8a}, R^{9a} and R^{10a} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl));

or a salt thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals such as humans.

3. The use of a compound of the formula Ib:



(Ib)

wherein:

ring C, R^1, R^2 and n are as defined in claim 1 with the proviso that R^2 is not hydrogen, R^{2a} is as defined in claim 2; and

Zb is -O- or -S-;

or a salt thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals such as humans.

4. A compound of the formula II:



(II)

wherein:

ring C, R^1, R^2 and n are as defined in claim 1 with the proviso that R^2 does not have any of the following values:

hydrogen, substituted or unsubstituted C_{1-5}alkyl, halogeno, C_{1-5}alkoxy, phenoxy or phenylC_{1-5}alkoxy;

R^{2a} is as defined in claim 2; and

Zb is as defined in claim 3;

or a salt thereof.

5. A compound as claimed in claim 4 wherein Zb is -O-.

6. A compound as claimed in claim 4 or claim 5 wherein R^{2a} is methoxy.

7. A compound as claimed in any one of claims 4-6 wherein ring C is a 5-membered heteroaromatic moiety which contains 1-3 heteroatoms selected independently from O, N and S.

8. A compound as claimed in any one of claims 4-7 wherein R^1 is a phenyl group or a 5-6-membered heteroaromatic group with 1-3 heteroatoms, selected independently from O, S and N, (linked via a ring carbon atom), which phenyl or heteroaromatic group is optionally substituted as defined in claim 1.

9. A compound as claimed in any one of claims 4-8 wherein R^2 represents hydroxy, halogeno, nitro, trifluoromethyl, C_{1-3}alkyl, cyano, amino or R^5X^1- [wherein X^1 is as defined in claim 1 and R^5 is selected from one of the following eighteen groups:

1) C_{1-4}alkyl which may be unsubstituted or substituted with one or more fluorine atoms, or C_{2-4}alkyl which may be unsubstituted or substituted with 1 or 2 groups selected from hydroxy and amino;

2) C_{2-3}alkylX^2C(O)R^{11} (wherein X^2 is as defined in claim 1 and R^{11} represents -$NR^{13}R^{14}$ or -OR^{15} (wherein R^{13}, R^{14} and R^{15} which may be the same or different are each C_{1-2}alkyl or C_{1-3}alkoxyethyl));

3) C_{2-4}alkylX^3R^{16} (wherein X^3 is as defined in claim 1 and R^{16} is a group selected from C_{1-3}alkyl, cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl which group is linked to X^3 through a carbon atom and which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-2}alkoxy and which cyclopentyl, cyclohexyl, pyrrolidinyl or piperidinyl group may carry one substituent selected from oxo, hydroxy, halogeno, C_{1-2}alkyl, C_{1-2}hydroxyalkyl and C_{1-2}alkoxy);

4) C_{2-3}alkylX^4C_{2-3}alkylX^5R^{22} (wherein X^4 and X^5 are as defined in claim 1 and R^{22} represents hydrogen or C_{1-3}alkyl);

5) C_{1-4}alkylR^{59} (wherein R^{59} is a group selected from pyrrolidinyl, piperazinyl, piperidinyl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl and 1,3-dithian-2-yl, which group is linked to C_{1-4}alkyl through a carbon atom and which group may carry 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-3}alkyl, C_{1-3}hydroxyalkyl, C_{1-3}alkoxy, C_{1-2}alkoxyC_{1-3}alkyl and C_{1-2}alkylsulphonylC_{1-3}alkyl) or C_{2-4}alkylR^{60} (wherein R^{60} is a group selected from morpholino, thiomorpholino, pyrrolidin-1-yl, piperazin-1-yl and piperidino which group may carry 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-3}alkyl, C_{1-3}hydroxyalkyl, C_{1-3}alkoxy, C_{1-2}alkoxyC_{1-3}alkyl and C_{1-2}alkylsulphonylC_{1-3}alkyl);

6) C_{3-4}alkenylR^{61} (wherein R^{61} represents R^{59} or R^{60} as defined herein);

7) C_{3-4}alkynylR^{61} (wherein R^{61} represents R^{59} or R^{60} as defined herein);

8) R^{29} (wherein R^{29} is as defined in claim 1);

9) C_{1-4}alkylR^{29} (wherein R^{29} is as defined in claim 1);

10) 1-R^{29}prop-1-en-3-yl or 1-R^{29}but-2-en-4-yl (wherein R^{29} is as defined in claim 1 with the proviso that when R^5 is 1-R^{29}prop-1-en-3-yl, R^{29} is linked to the alkenyl group via a carbon atom);

11) 1-R^{29}prop-1-yn-3-yl or 1-R^{29}but-2-yn-4-yl (wherein R^{29} is as defined in claim 1 with the proviso that when R^5 is 1-R^{29}prop-1-yn-3-yl, R^{29} is linked to the alkynyl group via a carbon atom);

12) C_{1-5}alkylX^6R^{29} (wherein X^6 and R^{29} are as defined in claim 1);

13) 1-($R^{29}X^7$)but-2-en-4-yl (wherein X^7 and R^{29} are as defined in claim 1);

14) 1-($R^{29}X^8$)but-2-yn-4-yl (wherein X^8 and R^{29} are as defined in claim 1);

15) C_{2-3}alkylX^9C_{1-2}alkylR^{29} (wherein X^9 and R^{29} are as defined in claim 1);

16) R^{28} (wherein R^{28} is as defined in claim 1);

17) C_{2-3}alkylX^9C_{1-2}alkylR^{28} (wherein X^9 and R^{28} are as defined in claim 1); and

18) C_{2-3}alkyl$R^{54}C_{1-2}$alkylX^9R^{55} (wherein X^9, R^{54} and R^{55} are as defined in claim 1);

and additionally wherein any C_{1-5}alkyl, C_{2-5}alkenyl or C_{2-5}alkynyl group in R^5X^1- may bear one or more substituents selected from hydroxy, halogeno and amino].

10. A compound as claimed in any one of claims 4-9 wherein R^2 represents 2-methoxyethoxy, 2-(2-methoxyethoxy)ethoxy, 3-methoxypropoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-(tetrahydropyran-4-yloxy)ethoxy, 3-(tetrahydropyran-4-yloxy)propoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(imidazol-1-yl)ethoxy, 3-(imidazol-1-yl)propoxy 2-(1,1-dioxothiomorpholino)ethoxy, 3-(1,1-dioxothiomorpholino)propoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, 2-(N-methoxyacetyl-N-methylamino)ethoxy, 3-(N-methoxyacetyl-N-methylamino)propoxy, N-methylpiperidin-3-ylmethoxy, 4-(pyrrolidin-1-yl)but-2-en-yloxy, 2-(2-oxopyrrolidin-1-yl)ethoxy, 3-(2-oxopyrrolidin-1-yl)propoxy, 2-(pyrrolidin-1-yl)ethoxy, 3-(pyrrolidin-1-yl)propoxy, 2-(2-(pyrrolidin-1-yl)ethoxy)ethoxy, 2-(2-(4-methylpiperazin-1-yl)ethoxy)ethoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-(methylpiperidino)ethoxy, 3-(methylpiperidino)propoxy, 2-(ethylpiperidino)ethoxy, 3-(ethylpiperidino)propoxy, 2-((2-methoxyethyl)piperidino)ethoxy, 3-((2-methoxyethyl)piperidino)propoxy, 2-((2-methylsulphonyl)ethylpiperidino)ethoxy, 3-((2-methylsulphonyl)ethylpiperidino)propoxy, piperidin-3-ylmethoxy, piperidin-4-ylmethoxy, 2-(piperidin-3-yl)ethoxy, 2-(piperidin-4-yl)ethoxy, 3-(piperidin-3-yl)propoxy, 3-(piperidin-4-yl)propoxy, 2-(methylpiperidin-3-yl)ethoxy, 2-(methylpiperidin-4-yl)ethoxy, 3-(methylpiperidin-3-yl)propoxy, 3-(methylpiperidin-4-yl)propoxy, 2-(ethylpiperidin-3-yl)ethoxy, 2-(ethylpiperidin-4-yl)ethoxy, 3-(ethylpiperidin-3-yl)propoxy, 3-(ethylpiperidin-4-

yl)propoxy, 2-((2-methoxyethyl)piperidin-3-yl)ethoxy, 2-((2-methoxyethyl)piperidin-4-yl)ethoxy, 3-((2-methoxyethyl)piperidin-3-yl)propoxy, 3-((2-methoxyethyl)piperidin-4-yl)propoxy, 2-((2-methylsulphonylethyl)piperidin-3-yl)ethoxy, 2-((2-methylsulphonylethyl)piperidin-4-yl)ethoxy, 3-((2-methylsulphonylethyl)piperidin-3-yl)propoxy, 3-((2-methylsulphonylethyl)piperidin-4-yl)propoxy, 1-isopropylpiperidin-2-ylmethyl, 1-isopropylpiperidin-3-ylmethyl, 1-isopropylpiperidin-4-ylmethyl, 2-(1-isopropylpiperidin-2-yl)ethyl, 2-(1-isopropylpiperidin-3-yl)ethyl, 2-(1-isopropylpiperidin-4-yl)ethyl, 3-(1-isopropylpiperidin-2-yl)propyl, 3-(1-isopropylpiperidin-3-yl)propyl, 3-(1-isopropylpiperidin-4-yl)propyl, 3-(4-methylpiperazin-1-yl)propoxy, 1-methylpiperidin-4-ylmethoxy, 1-(2-methylsulphonylethyl)piperidin-4-ylmethoxy, 1-(2-pyrrolidinylethyl)piperidin-4-ylmethoxy, 1-(3-pyrrolidinylpropyl)piperidin-4-ylmethoxy, 1-(2-piperidinylethyl)piperidin-4-ylmethoxy, 1-(3-piperidinylpropyl)piperidin-4-ylmethoxy, 1-(2-morpholinoethyl)piperidin-4-ylmethoxy, 1-(3-morpholinopropyl)piperidin-4-ylmethoxy, 1-(2-thiomorpholinoethyl)piperidin-4-ylmethoxy, 1-(3-thiomorpholinopropyl)piperidin-4-ylmethoxy, 1-(2-azetidinylethyl)piperidin-4-ylmethoxy or 1-(3-azetidinylpropyl)piperidin-4-ylmethoxy.

11. A compound as claimed in claim 4 selected from:

4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,

4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazoline,

6-methoxy-7-(2-(2-methoxyethoxy)ethoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,

4-(5-(3-furyl)pyrazol-3-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

6-methoxy-7-(3-morpholinopropoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,

7-(2-(imidazol-1-yl)ethoxy)-6-methoxy-4-(5-phenylpyrazol-3-yloxy)quinazoline,

4-(5-(4-chlorophenyl)pyrazol-3-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,

6-methoxy-7-(2-methoxyethoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,

4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)-6-methoxy-7-(2-(1,2,3-triazol-1-yl)ethoxy)quinazoline and

4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)-6-methoxy-7-(1-(2-methylsulphonylethyl)piperidin-4-ylmethoxy)quinazoline,
and salts thereof.

12. A compound as claimed in claim 4 selected from:
7-(2-methoxyethoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,
4-(5-(2-fluorophenyl)pyrazol-3-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
6-methoxy-7-(3-morpholinopropoxy)-4-(5-(3-nitrophenyl)pyrazol-3-yloxy)quinazoline,
6-methoxy-7-(3-morpholinopropoxy)-4-(5-(4-nitrophenyl)pyrazol-3-yloxy)quinazoline,
6-methoxy-7-(3-morpholinopropoxy)-4-(5-(4-pyridyl)pyrazol-3-yloxy)quinazoline,
4-(5-(4-fluorophenyl)pyrazol-3-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline, and
6-methoxy-7-(2-methoxyethoxy)-4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)quinazoline,
and salts thereof.

13. The use of a compound as claimed in claim 1 selected from:
6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)-4-(5-phenylpyrazol-3-ylamino)quinazoline
and
6,7-dimethoxy-4-(5-phenylpyrazol-3-yloxy)quinazoline
or a salt thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals such as humans.

14. A compound as claimed in any one of claims 4 to 12 in the form of a pharmaceutically acceptable salt.

15. A process for the preparation of a compound of formula I or salt thereof which comprises:
(a) the reaction of a compound of the formula III:



(III)

(wherein R^2 and m are as defined in claim 1 and L^1 is a displaceable moiety), with a compound of the formula IV:



(IV)

(wherein ring C, R^1, Z and n are as defined in claim 1);

(b) compounds of formula I and salts thereof wherein at least one R^2 is R^5X^1 wherein R^5 is as defined in claim 1 and X^1 is -O-, -S-, -OCO- or -NR^{10}- (wherein R^{10} independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) may be prepared by the reaction of a compound of the formula V:



(V)

(wherein ring C, Z, R^1, R^2 and n are as defined in claim 1 and X^1 is as defined herein in this section and s is an integer from 0 to 2) with a compound of formula VI:

R^5-L^1 (VI)

(wherein R^5 is as defined in claim 1 and L^1 is as defined herein);

(c) compounds of the formula I and salts thereof wherein at least one R^2 is R^5X^1 wherein R^5 is as defined in claim 1 and X^1 is -O-, -S-, -OCO- or -NR^{10}- (wherein R^{10} represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) may be prepared by the reaction of a compound of the formula VII:



(VII)

with a compound of the formula VIII:

R^5-X^1-H (VIII)

(wherein R^1, R^2, R^5, ring C, Z and n are as defined in claim 1 and s and L^1 are as defined herein and X^1 is as defined herein in this section);

(d) compounds of the formula I and salts thereof wherein at least one R^2 is R^5X^1 wherein X^1 is as defined in claim 1 and R^5 is C_{1-5}alkylR^{62}, wherein R^{62} is selected from one of the following nine groups:

1) $X^{10}C_{1-3}$alkyl (wherein X^{10} represents -O-, -S-, -SO_2-, -NR^{63}CO- or -$NR^{64}SO_2$- (wherein R^{63} and R^{64} which may be the same or different are each hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl);

2) $NR^{65}R^{66}$ (wherein R^{65} and R^{66} which may be the same or different are each hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl);

3) $X^{11}C_{1-5}alkylX^5R^{22}$ (wherein X^{11} represents -O-, -S-, $-SO_2-$, $-NR^{67}CO-$, $-NR^{68}SO_2-$ or $-NR^{69}-$ (wherein R^{67}, R^{68}, and R^{69} which may be the same or different are each hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$) and X^5 and R^{22} are as defined in claim 1);

4) R^{28} (wherein R^{28} is as defined in claim 1);

5) $X^{12}R^{29}$ (wherein X^{12} represents -O-, -S-, $-SO_2-$, $-NR^{70}CO-$, $-NR^{71}SO_2-$, or $-NR^{72}-$ (wherein R^{70}, R^{71}, and R^{72} which may be the same or different are each hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$) and R^{29} is as defined in claim 1);

6) $X^{13}C_{1-5}alkylR^{29}$, preferably $X^{13}C_{1-3}alkylR^{29}$, (wherein X^{13} represents -O-, -S-, $-SO_2-$, $-NR^{73}CO-$, $-NR^{74}SO_2-$ or $-NR^{75}-$ (wherein R^{73}, R^{74} and R^{75} each independently represents hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$) and R^{29} is as defined in claim 1);

7) R^{29} (wherein R^{29} is as defined in claim 1);

8) $X^{14}C_{1-3}alkylR^{28}$ (wherein X^{14} represents -O-, -S-, $-SO_2-$, $-NR^{76}CO-$, $-NR^{77}SO_2-$ or $-NR^{78}-$ (wherein R^{76}, R^{77} and R^{78} each independently represents hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$) and R^{28} is as defined in claim 1); and

9) $R^{54}C_{1-3}alkylX^9R^{55}$ (wherein R^{54}, R^{55} and X^9 are as defined in claim 1);

may be prepared by reacting a compound of the formula IX:



(IX)

(wherein X^1, R^1, R^2, ring C, Z and n are as defined in claim 1 and s and L^1 are as defined herein) with a compound of the formula X:

R^{62}-H (X)

(wherein R^{62} is as defined herein);

(e) compounds of the formula I and salts thereof wherein one or more of the substituents $(R^2)_m$ is represented by $-NR^{79}R^{80}$, where one (and the other is hydrogen) or both of R^{79} and R^{80} are C_{1-3}alkyl, may be prepared by the reaction of compounds of formula I wherein the substituent $(R^2)_m$ is an amino group and an alkylating agent;

(f) compounds of the formula I and salts thereof wherein X^1 is -SO- or $-SO_2-$ may be prepared by oxidation from the corresponding compound in which X^1 is -S- or -SO-;

and when a salt of a compound of formula I is required, reaction of the compound obtained with an acid or base whereby to obtain the desired salt.

16. A pharmaceutical composition which comprises as active ingredient a compound of formula I or a pharmaceutically acceptable salt thereof as claimed in any one of claims 4 to 12 in association with a pharmaceutically acceptable excipient or carrier.

17. A method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof.

sub B3

add B4

add B5